Free Trial
NASDAQ:XOMA

XOMA Royalty Q4 2024 Earnings Report

XOMA Royalty logo
$27.25 +2.48 (+10.01%)
Closing price 04:00 PM Eastern
Extended Trading
$27.20 -0.05 (-0.17%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Royalty EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.17
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$8.70 million
Expected Revenue
$8.75 million
Beat/Miss
Missed by -$47.00 thousand
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 17, 2025
Conference Call Time
10:30AM ET

Upcoming Earnings

XOMA Royalty's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 7:45 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Royalty Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
HilleVax to be acquired by XOMA Royalty
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Royalty Profile

More Earnings Resources from MarketBeat